Tech Company Inital Public Offerings
CureVac IPO
Headquartered in Tübingen, CureVac went public.
Transaction Overview
Company Name
Announced On
8/13/2020
Transaction Type
IPO
Amount
$213,280,000
Proceeds Purpose
We currently intend to use the net proceeds from the offering and the concurrent private placement, together with cash and cash equivalents on hand as follows: [i] to fund the Company's mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3; [ii] to fund the expansion of the Company's short term manufacturing capabilities; [iii] to advance the Company's lead oncology program, CV8102, through the completion of the Phase 2 clinical trial; [iv] to advance the Company's vaccine program, CV7202 in rabies through the completion of the Phase 2 clinical trial; [v] to invest in further development of the Company's mRNA technology platform and to advance the development of other preclinical and clinical programs; and [vi] the remainder for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
15 Paul-Ehrlich-Strasse
Tübingen, 72076
Germany
Tübingen, 72076
Germany
Phone
Website
Email Address
Overview
CureVac (Nasdaq: CVAC) is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/13/2020: Reify Health venture capital transaction
Next: 8/13/2020: iRestify venture capital transaction
Share this article
About Database of VC Transactions
We report on tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs